of the life claims declined, 0.85 per cent were due to mis-representation and 0.16 per cent due to the definition of terminal illness not being met. . september 2006 (19).understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study..
understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study..